Literature DB >> 33964313

Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease.

Simon A Carter1, Charlotte Logeman2, Martin Howell3, Dan Cattran4, Liz Lightstone5, Arvind Bagga6, Sean J Barbour7, Jonathan Barratt8, John Boletis9, Dawn J Caster10, Rosanna Coppo11, Fernando C Fervenza12, Jürgen Floege13, Michelle A Hladunewich14, Jonathan J Hogan15, A Richard Kitching16, Richard A Lafayette17, Ana Malvar18, Jai Radhakrishnan19, Brad H Rovin20, Nicole Scholes-Robertson3, Hérnan Trimarchi21, Hong Zhang22, Yeoungjee Cho23, Louese Dunn24, Debbie S Gipson25, Adrian Liew26, Benedicte Sautenet27, Andrea K Viecelli28, David Harris29, David W Johnson23, Angela Yee-Moon Wang30, Armando Teixeira-Pinto3, Stephen I Alexander2, Adam Martin2, Allison Tong3, Jonathan C Craig31.   

Abstract

Outcomes relevant to treatment decision-making are inconsistently reported in trials involving glomerular disease. Here, we sought to establish a consensus-derived set of critically important outcomes designed to be reported in all future trials by using an online, international two-round Delphi survey in English. To develop this, patients with glomerular disease, caregivers and health professionals aged 18 years and older rated the importance of outcomes using a Likert scale and a Best-Worst scale. The absolute and relative importance was assessed and comments were analyzed thematically. Of 1198 participants who completed Round 1, 734 were patients/caregivers while 464 were health care professionals from 59 countries. Of 700 participants that completed Round 2, 412 were patients/caregivers and 288 were health care professionals. Need for dialysis or transplant, kidney function, death, cardiovascular disease, remission-relapse and life participation were the most important outcomes to patients/caregivers and health professionals. Patients/caregivers rated patient-reported outcomes higher while health care professionals rated hospitalization, death and remission/relapse higher. Four themes explained the reasons for their priorities: confronting death and compounded suffering, focusing on specific targets in glomerular disease, preserving meaning in life, and fostering self-management. Thus, consistent reporting of these critically important outcomes in all trials involving glomerular disease is hoped to improve patient-centered decision-making.
Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  consensus; glomerulonephritis; patient outcome assessment; treatment outcome; trials

Mesh:

Year:  2021        PMID: 33964313     DOI: 10.1016/j.kint.2021.04.027

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   18.998


  1 in total

1.  A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops.

Authors:  Simon A Carter; Liz Lightstone; Dan Cattran; Allison Tong; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn J Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle A Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hernán Trimarchi; Hong Zhang; Samaya Anumudu; Yeoungjee Cho; Talia Gutman; Emma O'Lone; Andrea K Viecelli; Eric Au; Karolis Azukaitis; Amanda Baumgart; Amelie Bernier-Jean; Louese Dunn; Martin Howell; Angela Ju; Charlotte Logeman; Melissa Nataatmadja; Benedicte Sautenet; Ankit Sharma; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-30       Impact factor: 8.237

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.